Madrigal Pharmaceuticals, Inc. (MDGL) is a Healthcare stock trading at $516.73 (as of 2026-08-21), with a market capitalization of $11.94B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapeutic candidates focused on cardiovascular, metabolic, and liver diseases. Its lead candidate, resmetirom, is in Phase III for non-alcoholic steatohepatitis, and it also develops MGL-3745 as a backup; the company has a research, development, and commercialization agreement with Hoffmann-La Roche.
Understand Madrigal Pharmaceuticals, Inc.: how it makes money
Madrigal Pharmaceuticals develops and commercializes therapeutic candidates for cardiovascular, metabolic, and liver diseases, led by Resmetirom (ResDifera), a liver-directed selective thyroid hormone receptor agonist, and it makes money through ResDifera net sales.
Madrigal's profit trajectory depends on whether ResDifera net sales keep scaling as the company grows patients actively on therapy, supported by prescriber and coverage dynamics, while it continues Phase III development and other pipeline investment (operating losses remain evident).
Revenue by segment (latest quarter)
ResDifera
$0.3B
Business quality (Weak): The company has a commercial product revenue base (ResDifera net sales) but is still loss-making on an operating basis, and its key clinical program is in Phase III, so results are likely sensitive to patient uptake and ongoing development progress.
Bull case
Commercial traction behind the revenue line: The operational KPIs focus on patients actively on ResDifera therapy and ResDifera coverage, which indicates the business model is tied to expanding real world use.
Market expansion runway tied to coverage and prescriber breadth: ResDifera coverage as a percentage of commercial lives and ResDifera prescribers breadth suggest the company can expand adoption beyond its current footprint.
Pipeline supports longer term optionality: Madrigal also develops MGL-3745 as a backup compound to resmetirom, and it has multiple metabolic dysfunction-associated steatohepatitis pipeline programs across development stages.
Bear case
Ongoing operating losses: The latest quarter shows an operating margin of -29.8, which means profitability has not yet materialized despite revenue generation.
Clinical and execution risk for the lead program: Resmetirom is in Phase III clinical trials for non-alcoholic steatohepatitis, so future outcomes could affect the company’s outlook.
Uptake is not yet deep relative to the diagnosed population: The penetration of diagnosed F2 to F3 metabolic dysfunction-associated steatohepatitis patients treated is 7.0, which highlights that adoption is still early.
Competition or treatment mix could influence incremental growth: Concomitant glucagon-like peptide-1 usage among ResDifera patients is 25.0, and there is a 50.0 share of ResDifera patients on or previously on glucagon-like peptide-1, which could affect incremental prescribing depending on how patients are managed.